Tilray Brands Extends Global Reach With Key Approvals and Launches

Tilray Medical is aggressively expanding its global medical cannabis presence, establishing a licensed joint venture in Panama, launching new products in Germany, and forming a strategic distribution partnership in Italy, while also introducing edibles in Australia. These international growth initiatives coincide with Tilray Brands' stock gaining 34.8% over the past three months, outperforming the industry, and an improved 2025 loss per share estimate, reflecting positive market sentiment amidst broader sector expansion by peers like Village Farms and Curaleaf.

Analysis

Tilray Medical is aggressively expanding its global footprint, securing a medical cannabis license in Panama via a joint venture and launching five new EU GMP-certified cannabis flower products in Germany. Strategic partnerships, such as with Molteni in Italy for extract distribution and the introduction of edibles in Australia, underscore its commitment to innovation and market penetration. These initiatives solidify Tilray's position as a global leader in medical cannabis, leveraging new genetics and patient-focused solutions.

Tilray Brands' stock has demonstrated robust performance, gaining 34.8% over the past three months, significantly outperforming the industry's 3.2% decline and the S&P 500's 7.1% growth. The company trades at a forward 12-month Price-to-Sales (P/S) of 2.94X, below the industry average of 3.16X, suggesting a potentially discounted valuation. Furthermore, the 2025 loss per share estimate improved by 6 cents in the last 30 days, contributing to a Zacks Rank #2 (Buy) rating.

The broader medical cannabis sector is experiencing significant international growth, as evidenced by peers like Village Farms International and Curaleaf Holdings. Village Farms reported a 690% year-over-year increase in international medical export sales and expanded into the Netherlands, while Curaleaf secured a license in Turkey and launched products in Australia. This indicates a favorable regulatory and market environment supporting global expansion strategies across the industry.

Key Decisions for Investors

• Investors should monitor Tilray's continued international market penetration and regulatory developments, particularly in new markets like Panama and Italy, as these are key drivers for long-term growth.
• Given the stock's recent outperformance and discounted P/S relative to the industry, a deeper dive into Tilray's fundamental valuation metrics and future earnings projections may be warranted.
• Observe the sustained momentum in international medical cannabis sales across the sector, as highlighted by Village Farms, to gauge the overall health and expansion potential of the global market.